IMMUNOTECH BIOPHARM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.31 HKD | -1.78% |
|
-4.06% | -33.80% |
| 29/03 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
| 28/03 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 2.1B 16.47B 175B |
|---|---|---|---|---|---|
| Net income 2021 | -354M -2.77B -29.52B | Net income 2022 | -318M -2.49B -26.51B | EV / Sales 2021 | - |
| Net cash position 2021 | 242M 1.9B 20.2B | Net Debt 2022 | 70.35M 551M 5.87B | EV / Sales 2022 | - |
| P/E ratio 2021 |
-19.9
x | P/E ratio 2022 |
-6.6
x | Employees | 211 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 44.48% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.78% | ||
| 1 week | -4.06% | ||
| Current month | -11.26% | ||
| 1 month | -11.26% | ||
| 3 months | -17.46% | ||
| 6 months | -19.07% | ||
| Current year | -33.80% |
1 week
3.02
3.58
1 month
3.023.70
Current year
3.025.00
1 year
3.025.00
3 years
3.0222.45
5 years
3.0222.45
10 years
3.0222.45
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Wang
CEO | Chief Executive Officer | 57 | 23/19/23 |
Ning Yang
DFI | Director of Finance/CFO | 43 | 01/19/01 |
Yu Zhang
CTO | Chief Tech/Sci/R&D Officer | 60 | 24/18/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Hua Wang
BRD | Director/Board Member | 60 | 24/23/24 |
Ying Dian Wang
BRD | Director/Board Member | 63 | 01/19/01 |
Ran Tao
BRD | Director/Board Member | 59 | 23/21/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 4 M€ | -27.92% | ||
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.31 | -1.78% | 22,000 |
| 25/24/25 | 3.37 | +2.12% | 2,000 |
| 24/24/24 | 3.3 | +5.10% | 60,000 |
| 23/24/23 | 3.14 | -6.82% | 46,000 |
| 22/24/22 | 3.37 | -2.32% | 0 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.80% | 218M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6978 Stock
